共 50 条
- [2] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I StudyClinical Drug Investigation, 2018, 38 : 945 - 954Tadao AkizawaRyutaro ShimazakiMasanari ShiramotoMasafumi Fukagawa
- [3] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I StudyCLINICAL DRUG INVESTIGATION, 2018, 38 (10) : 945 - 954Akizawa, TadaoShimazaki, RyutaroShiramoto, MasanariFukagawa, Masafumi
- [4] Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”Clinical Drug Investigation, 2019, 39 : 109 - 111Tadao AkizawaRyutaro ShimazakiMasanari ShiramotoMasafumi Fukagawa
- [5] Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study"CLINICAL DRUG INVESTIGATION, 2019, 39 (01) : 109 - 111Akizawa, TadaoShimazaki, RyutaroShiramoto, MasanariFukagawa, Masafumi
- [6] First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese ParticipantsDRUGS IN R&D, 2022, 22 (02) : 131 - 140Koiwa, FumihikoYazawa, RieFukagawa, MasafumiHonda, DaisukeAkizawa, Tadao
- [7] First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese ParticipantsDrugs in R&D, 2022, 22 : 131 - 140Fumihiko KoiwaRie YazawaMasafumi FukagawaDaisuke HondaTadao Akizawa
- [8] Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I studyCTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (11):Miyamoto, KyokoMiller, Robert M.Voors-Pette, ChristineOosterhaven, Jart A. F.van den Dobbelsteen, MariekeMihara, KatsuhiroGeldof, MarianSato, YujiMatsuda, NaomiKirita, ShirouSawa, MasaakiArimura, Akinori
- [9] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjectsCELL REPORTS MEDICINE, 2023, 4 (09)Ahmadi, Ali R.Atiee, GeorgeChapman, BartReynolds, LaurieSun, JohnCameron, Andrew M.Wesson, Russell N.Burdick, James F.Sun, Zhaoli
- [10] A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy SubjectsARTHRITIS & RHEUMATOLOGY, 2017, 69Gul, AhmetUlker, SibelSenturk, Recep SelimTurk, Ugur OnselGurgun, CemilLavrovsky, YanSamsonov, MikhailOzen, SebnemAltinel, Serdar